408 related articles for article (PubMed ID: 17665487)
1. Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis.
Wolfe F; Rasker JJ; Boers M; Wells GA; Michaud K
Arthritis Rheum; 2007 Aug; 57(6):935-42. PubMed ID: 17665487
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.
de Punder YM; Fransen J; Kievit W; Houtman PM; Visser H; van de Laar MA; van Riel PL
Rheumatology (Oxford); 2012 Sep; 51(9):1610-7. PubMed ID: 22539487
[TBL] [Abstract][Full Text] [Related]
3. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
Sesin CA; Bingham CO
Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
[TBL] [Abstract][Full Text] [Related]
4. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
El Miedany Y; Youssef SS; El Gaafary M
J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
[TBL] [Abstract][Full Text] [Related]
5. Minimal disease activity for rheumatoid arthritis: a preliminary definition.
Wells GA; Boers M; Shea B; Brooks PM; Simon LS; Strand CV; Aletaha D; Anderson JJ; Bombardier C; Dougados M; Emery P; Felson DT; Fransen J; Furst DE; Hazes JM; Johnson KR; Kirwan JR; Landewé RB; Lassere MN; Michaud K; Suarez-Almazor M; Silman AJ; Smolen JS; Van der Heijde DM; van Riel PL; Wolfe F; Tugwell PS
J Rheumatol; 2005 Oct; 32(10):2016-24. PubMed ID: 16206362
[TBL] [Abstract][Full Text] [Related]
6. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes.
Wolfe F; Michaud K; Pincus T; Furst D; Keystone E
Arthritis Rheum; 2005 Dec; 52(12):3873-9. PubMed ID: 16320335
[TBL] [Abstract][Full Text] [Related]
7. Most people over age 50 in the general population do not meet ACR remission criteria or OMERACT minimal disease activity criteria for rheumatoid arthritis.
Sokka T; Mäkinen H; Hannonen P; Pincus T
Rheumatology (Oxford); 2007 Jun; 46(6):1020-3. PubMed ID: 17405761
[TBL] [Abstract][Full Text] [Related]
8. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
Keystone E; Freundlich B; Schiff M; Li J; Hooper M
J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
[TBL] [Abstract][Full Text] [Related]
9. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
10. The problem of rheumatoid arthritis disease activity and remission in clinical practice.
Shaver TS; Anderson JD; Weidensaul DN; Shahouri SH; Busch RE; Mikuls TR; Michaud K; Wolfe F
J Rheumatol; 2008 Jun; 35(6):1015-22. PubMed ID: 18412311
[TBL] [Abstract][Full Text] [Related]
11. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
[TBL] [Abstract][Full Text] [Related]
12. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis.
Liang GC; Cordero M; Dyer A; Chang RW
J Rheumatol; 2005 Sep; 32(9):1662-5. PubMed ID: 16142857
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
14. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission.
Sokka T; Pincus T
J Rheumatol; 2003 Jun; 30(6):1138-46. PubMed ID: 12784382
[TBL] [Abstract][Full Text] [Related]
15. Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
Kapral T; Dernoschnig F; Machold KP; Stamm T; Schoels M; Smolen JS; Aletaha D
Arthritis Res Ther; 2007; 9(4):R72. PubMed ID: 17662115
[TBL] [Abstract][Full Text] [Related]
16. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis.
Radovits BJ; Kievit W; Fransen J; van de Laar MA; Jansen TL; van Riel PL; Laan RF
Ann Rheum Dis; 2009 Sep; 68(9):1470-3. PubMed ID: 19015210
[TBL] [Abstract][Full Text] [Related]
17. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study.
Lee SJ; Chang H; Yazici Y; Greenberg JD; Kremer JM; Kavanaugh A
J Rheumatol; 2009 Aug; 36(8):1611-7. PubMed ID: 19369454
[TBL] [Abstract][Full Text] [Related]
18. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
Welsing PM; Fransen J; van Riel PL
Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
[TBL] [Abstract][Full Text] [Related]
19. "5D" Outcome in 52 patients with rheumatoid arthritis surviving 20 years after initial disease modifying antirheumatic drug therapy.
Capell H; McCarey D; Madhok R; Hampson R
J Rheumatol; 2002 Oct; 29(10):2099-105. PubMed ID: 12375318
[TBL] [Abstract][Full Text] [Related]
20. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.
Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
Rheumatology (Oxford); 2008 Jun; 47(6):872-6. PubMed ID: 18400836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
